Shots:

• Moberg to receive $1.69M upfront- $56.39M milestone- royalties & supply fees based on sales of MOB-015. Bayer to get exclusive commercialization rights for MOB-015 in EU post completion of its P-III
• The focus of the agreement is to develop MOB-015 based on Moberg’s formulation of terbinafine offering therapies & for the advancement of dermatological products for nail fungus (onychomycosis)
• Moberg Pharma’s MOB-015 is a topical formulation of terbinafine- evaluated in P-III study in 800 patients for onychomycosis at North America and EU for 52 weeks- with its expected results in Q4’19 and Q4’20 respectively

Ref: PRNewswire  | Image: Twitter